Purpose. To compare Ologen implant versus mitomycin-C (MMC) in combined trabeculotomy and trabeculectomy as a treatment
of primary congenital glaucoma. Setting. Sohag University Hospital, Egypt. Design. A prospective comparative study. Methods.
Thirty-four eyes of twenty-one patients with primary congenital glaucoma were included in this study. All patients were
subjected to preoperative evaluation including complete anterior segment examination under general anesthesia. The patients
were divided into two groups: patients of the first group (group A) underwent combined trabeculotomy and trabeculectomy
with Ologen implantation while those of the second group (group B) underwent combined trabeculotomy and trabeculectomy
with MMC application. Results. Postoperatively, the IOP in group A was as follows: 8 eyes developed IOP levels less than
14mmHg (complete success), 3 eyes had levels between 14 and 16mmHg (accepted result), 2 eyes had levels between 16
and 20mmHg (guarded result), and only 2 eyes showed levels exceeding 20mmHg (failed procedure), while in group B, 7
eyes showed complete success, 3 eyes had accepted result, 3 eyes had guarded result, and 2 eyes had failed procedure.
Conclusion. Ologen is a safe and effective adjuvant in combined trabeculotomy and trabeculectomy for treatment of primary
congenital glaucoma.